Amylin in Milan
CagriSema lowers HbA1c by 0.16 points and weight by 4 points more than semaglutide in type 2 diabetes (REIMAGINE 2), zenagamtide follows
Amylin day at EASD 2026 in Milan. REIMAGINE 2 (Lancet Diabetes and Endocrinology) randomised 2,713 adults with type 2 diabetes on metformin with or without an SGLT2 inhibitor (mean HbA1c 8.2 percent, BMI 25 or higher) to CagriSema 2.4/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, lower doses or placebo for 68 weeks. HbA1c fell by 1.91 versus 1.75 percentage points (difference -0.16, 95% CI -0.27 to -0.05, p=0.0035), body weight by 14.2 versus 10.2 percent; adverse events, mainly gastrointestinal, in 86.9 versus 81.2 percent. REIMAGINE 1 (189 treatment-naive people, 40 weeks: HbA1c -1.8 points, weight -13.8 percent versus placebo) and zenagamtide phase 2b (HbA1c -1.71 points, weight -14.6 percent at 36 weeks) were also presented. Amylin adds a small glycaemic gain and a clear weight gain over semaglutide alone; cardiovascular outcome data are pending. Sponsor-run trials.
Join us
Join the Global Primary Care Cardio Network. Membership is free.
Would you like to tell us more about yourself?
Interests
We will send you an email with a link to confirm your registration.
